Delali A. currently serves as the Regional Executive Director for DNDi North America and is the Principal and Founder of R8 Collective, both positions held since 2023. With extensive experience in the biotechnology and pharmaceutical sectors, Delali A. has also been a member of the Board of Directors at ReSurge International since 2019 and held the role of Chief Operating Officer at 54gene until December 2022. Previous positions include Head of Market Access for East Africa at Roche and various roles at Genentech, including Group Product Manager for BioOncology Access Solutions. Delali A. began a career in engineering with Merck and Johnson & Johnson in the early 2000s. Academic qualifications include an MBA from Babson F.W. Olin Graduate School of Business, a Master's in Biotechnology and Biopharmaceutical Engineering from the University of Pennsylvania, and a Bachelor's degree in Biomedical Engineering from the University of Rochester.
This person is not in any teams
This person is not in any offices
Drugs for Neglected Diseases initiative - DNDi
2 followers
The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization. We discover, develop, and deliver treatments for neglected patients around the world. Our treatments are affordable and patient-friendly – and have already saved millions of lives. We are researching new treatments for people living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. Together with our partners, we are working on over 40 projects, including more than 20 new chemical entities. We are also running over 20 clinical trials. When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, they dedicated a portion of the award to addressing this fatal imbalance and exploring a new, alternative, not-for-profit model for developing drugs for neglected patients. As a result in 2003, MSF, the World Health Organization, and five international research institutions founded DNDi.